DK507886D0 - Infusionsoplaesninger af 1-cyclopropyl-6-fluor-1,4-dihydro-4-oxo-7-(1-piperazinyl)-quinolin-3-carboxylsyre, lyofilisater og koncentrater og fremgangsmaade til deres fremstilling samt deres anvendelse - Google Patents

Infusionsoplaesninger af 1-cyclopropyl-6-fluor-1,4-dihydro-4-oxo-7-(1-piperazinyl)-quinolin-3-carboxylsyre, lyofilisater og koncentrater og fremgangsmaade til deres fremstilling samt deres anvendelse

Info

Publication number
DK507886D0
DK507886D0 DK507886A DK507886A DK507886D0 DK 507886 D0 DK507886 D0 DK 507886D0 DK 507886 A DK507886 A DK 507886A DK 507886 A DK507886 A DK 507886A DK 507886 D0 DK507886 D0 DK 507886D0
Authority
DK
Denmark
Prior art keywords
lyophilizates
piperazinyl
quinoline
cyclopropyl
dihydro
Prior art date
Application number
DK507886A
Other languages
English (en)
Other versions
DK175494B1 (da
DK507886A (da
Inventor
Robert Frank Lammens
Hans Friedrich Mahler
Peter Serno
Original Assignee
Bayer Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=6284294&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK507886(D0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Ag filed Critical Bayer Ag
Publication of DK507886D0 publication Critical patent/DK507886D0/da
Publication of DK507886A publication Critical patent/DK507886A/da
Application granted granted Critical
Publication of DK175494B1 publication Critical patent/DK175494B1/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dermatology (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
DK198605078A 1985-10-24 1986-10-23 Infusionsoplösninger af 1-cyclopropyl-6-fluor-1,4-dihydroxy-4-oxo-7-(1-piperazinyl)-quinolin-3-carboxylsyre, lyofilisater deraf og fremgangsmåde til deres fremstilling samt deres anvendelse DK175494B1 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19853537761 DE3537761A1 (de) 1985-10-24 1985-10-24 Infusionsloesungen der 1-cyclopropyl-6-fluor-1,4-dihydro-4-oxo-7- (1-piperazinyl)-chinolin-3-carbonsaeure
DE3537761 1985-10-24

Publications (3)

Publication Number Publication Date
DK507886D0 true DK507886D0 (da) 1986-10-23
DK507886A DK507886A (da) 1987-04-25
DK175494B1 DK175494B1 (da) 2004-11-08

Family

ID=6284294

Family Applications (1)

Application Number Title Priority Date Filing Date
DK198605078A DK175494B1 (da) 1985-10-24 1986-10-23 Infusionsoplösninger af 1-cyclopropyl-6-fluor-1,4-dihydroxy-4-oxo-7-(1-piperazinyl)-quinolin-3-carboxylsyre, lyofilisater deraf og fremgangsmåde til deres fremstilling samt deres anvendelse

Country Status (27)

Country Link
US (1) US4957922A (da)
EP (1) EP0219784B1 (da)
JP (1) JPH0714879B2 (da)
KR (1) KR940002664B1 (da)
AR (1) AR244085A1 (da)
AT (1) ATE59003T1 (da)
AU (1) AU571796B2 (da)
CA (1) CA1282006C (da)
CY (1) CY1729A (da)
DD (1) DD252125A5 (da)
DE (2) DE3537761A1 (da)
DK (1) DK175494B1 (da)
ES (1) ES2021571B3 (da)
FI (1) FI84555C (da)
GR (1) GR3002544T3 (da)
HK (1) HK115593A (da)
HU (1) HUT42952A (da)
IE (1) IE59385B1 (da)
IL (1) IL80380A (da)
NO (1) NO864022L (da)
NZ (1) NZ218016A (da)
PH (1) PH26419A (da)
PL (1) PL152336B1 (da)
PT (1) PT83588B (da)
SU (1) SU1487801A3 (da)
UA (1) UA8033A1 (da)
ZA (1) ZA868057B (da)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5281596A (en) * 1986-02-19 1994-01-25 Bayer Aktiengesellschaft Antibacterial drugs for fish
JPS62192321A (ja) * 1986-02-19 1987-08-22 Bayer Japan Kk 魚類用抗菌剤
FI883337A (fi) * 1987-07-16 1989-01-17 Bristol Myers Co Icke-vattenloesningar av doxorubicinhydroklorin.
FI883338A (fi) * 1987-07-16 1989-01-17 Bristol Myers Co Vattenloesningar av doxorubicinhydroklorid.
JPH01175935A (ja) * 1987-12-28 1989-07-12 Kyorin Pharmaceut Co Ltd 凍結乾燥注射剤
DE3902079A1 (de) * 1988-04-15 1989-10-26 Bayer Ag I.m. injektionsformen von gyrase-inhibitoren
NZ232740A (en) * 1989-04-20 1992-06-25 Riker Laboratories Inc Solution for parenteral administration comprising a 1h-imidazo(4,5-c) quinolin-4-amine derivative, an acid and a tonicity adjuster
FR2655545B1 (fr) * 1989-12-11 1994-06-10 Rhone Poulenc Sante Nouvelle application therapeutique des derives des fluoroquinolones.
US6300361B1 (en) * 1990-07-25 2001-10-09 Novartis Ag Stabilized pharmaceutical compositions comprising acid donors
FR2681863B1 (fr) * 1991-09-27 1995-02-03 Rhone Dpc Europ Solution de sparfloxacine sa preparation et sel la constituant.
KR0159540B1 (ko) * 1992-01-21 1998-12-01 김정순 퀴놀론-카복실산의 염 및 그 함유조성물
US5290794A (en) * 1992-10-27 1994-03-01 Warner Lambert Co. Soluble calcium lactate antibacterial complexes as non-irritating parenteral forms
ES2088742B1 (es) 1994-06-29 1997-03-16 Salvat Lab Sa Composicion antibiotica de aplicacion otica.
DE19500784A1 (de) * 1995-01-13 1996-07-18 Bayer Ag Enrofloxacin-Injektions- oder Infusionslösungen
JPH08213881A (ja) * 1995-02-02 1996-08-20 Fujitsu Ltd 周波数制御回路
US5800833A (en) * 1995-02-27 1998-09-01 University Of British Columbia Method for loading lipid vesicles
US5843930A (en) * 1995-06-06 1998-12-01 Bayer Corporation Method of treating otitis with ciprofloxacin-hydrocortisone suspension
NZ309624A (en) * 1995-06-06 1999-04-29 Bayer Ag Non-irritating, non-sensitizing, non-ototoxic (harmful to the ears) antibacterial compositions
IT1280428B1 (it) * 1995-07-14 1998-01-20 R R A S R L Composizione farmaceutica per uso topico
ES2106680B1 (es) * 1995-08-03 1998-07-01 Vita Invest Sa Composiciones acuosas conteniendo ciprofloxacino y utilizacion y procedimiento correspondientes.
DE19730023A1 (de) * 1997-07-11 1999-01-14 Bayer Ag Hochreine Ciprofloxacin-Infusion
ATE555780T1 (de) * 1997-10-24 2012-05-15 John P Blass Nahrungsergänzungsmittel für metabolische hirnleistungsstörungen
US6716830B2 (en) 1998-09-30 2004-04-06 Alcon, Inc. Ophthalmic antibiotic compositions containing moxifloxacin
DE19937116A1 (de) 1999-08-06 2001-02-08 Bayer Ag Moxifloxacin Kochsalzformulierung
DE10018783A1 (de) * 2000-04-15 2001-10-25 Fresenius Kabi De Gmbh Lagerstabile Infusionslösung des Ciprofloxacins mit verringertem Säuregehalt
ES2305065T3 (es) * 2000-04-24 2008-11-01 Daiichi Sankyo Company, Limited Preparacion liquida estable que contiene sitafloxacina.
DE10048510A1 (de) * 2000-09-29 2002-05-16 Fresenius Kabi De Gmbh Lagerstabile Infusionslösung des Ciprofloxacins mit verringertem Säuregehalt
JP2006151808A (ja) * 2002-12-24 2006-06-15 Dai Ichi Seiyaku Co Ltd 抗菌性水性製剤
US6861422B2 (en) * 2003-02-26 2005-03-01 Boehringer Ingelheim Pharma Gmbh & Co. Kg Dihydropteridinones, processes for preparing them and their use as pharmaceutical compositions
DE102004005186B3 (de) * 2004-02-02 2005-10-13 Krka Tovarna Zdravil, D.D. Verfahren zur Herstellung von gereinigtem Ciprofloxacin
WO2005123137A2 (en) * 2004-06-18 2005-12-29 Ranbaxy Laboratories Limited Lyophilized pharmaceutical composition comprising moxifloxacin hydrochloride
DE102004029784A1 (de) * 2004-06-21 2006-01-05 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue 2-Benzylaminodihydropteridinone, Verfahren zur deren Herstellung und deren Verwendung als Arzneimittel
DE102004033670A1 (de) * 2004-07-09 2006-02-02 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Pyridodihydropyrazinone, Verfahren zu Ihrer Herstellung und Ihre Verwendung als Arzneimittel
US7728134B2 (en) * 2004-08-14 2010-06-01 Boehringer Ingelheim International Gmbh Hydrates and polymorphs of 4[[(7R)-8-cyclopentyl-7-ethyl-5,6,7,8-tetrahydro-5-methyl-6-oxo-2-pteridinyl]amino]-3-methoxy-N-(1-methyl-4-piperidinyl)-benzamide, process for their manufacture and their use as medicament
US20060035903A1 (en) * 2004-08-14 2006-02-16 Boehringer Ingelheim International Gmbh Storage stable perfusion solution for dihydropteridinones
US20060074088A1 (en) * 2004-08-14 2006-04-06 Boehringer Ingelheim International Gmbh Dihydropteridinones for the treatment of cancer diseases
US20060058311A1 (en) * 2004-08-14 2006-03-16 Boehringer Ingelheim International Gmbh Combinations for the treatment of diseases involving cell proliferation
US7759485B2 (en) * 2004-08-14 2010-07-20 Boehringer Ingelheim International Gmbh Process for the manufacture of dihydropteridinones
EP1630163A1 (de) * 2004-08-25 2006-03-01 Boehringer Ingelheim Pharma GmbH & Co.KG Dihydropteridinonderivative, Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel
EP1632493A1 (de) * 2004-08-25 2006-03-08 Boehringer Ingelheim Pharma GmbH & Co.KG Dihydropteridinonderivative, Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel
DE102004054873A1 (de) 2004-11-12 2006-05-18 Bayer Healthcare Ag Behandlung von Mastitis
DE102004058337A1 (de) * 2004-12-02 2006-06-14 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Herstellung von annelierten Piperazin-2-on Derivaten
DE102005055385A1 (de) * 2004-12-09 2006-06-14 Bayer Healthcare Ag Arzneimittel zur hygienischen Applikation im Ohr
JP5002462B2 (ja) * 2004-12-09 2012-08-15 バイエル・アニマル・ヘルス・ゲゼルシヤフト・ミツト・ベシユレンクテル・ハフツング 酸によるグルココルチコイドエステルの安定化
FR2896416B1 (fr) * 2006-01-24 2010-08-13 Vetoquinol Composition anti-infectieuse comprenant un compose de type pyrido (3,2,1-ij)-benzoxadiazine
US7439358B2 (en) 2006-02-08 2008-10-21 Boehringer Ingelheim International Gmbh Specific salt, anhydrous and crystalline form of a dihydropteridione derivative
US20070197548A1 (en) * 2006-02-17 2007-08-23 Murthy Yerramilli V S Fluoroquinolone compositions
WO2008114861A1 (ja) * 2007-03-22 2008-09-25 Daiichi Sankyo Company, Limited アルコール類含有キノロン医薬組成物
AU2008239966C1 (en) * 2007-04-13 2012-03-29 Dong Wha Pharmaceutical Co., Ltd. Aspartate of 1-cyclopropyl-6-fluoro-7-(8-methoxyimino-2,6-diaza- spiro[3.4]oct-6-yl)-4-oxo-1,4-dihydro-[1,8]naphthyridine-3-carboxylic acid, method for preparing the same, and antimicrobial pharmaceutical composition comprising the same
JP5217276B2 (ja) * 2007-07-19 2013-06-19 ニプロ株式会社 注射用抗菌剤の製造方法
US8329695B2 (en) * 2007-08-03 2012-12-11 Boehringer Ingelheim International Gmbh Crystalline form of the free base N-[trans-4-[4-(cyclopropylmethyl)-1-piperazinyl]cyclohexyl]-4-[[(7r)-7-ethyl-5,6,7,8-tetrahydro-5-methyl-8-(1-methylethyl)-6-oxo-2-pteridinyl]amino]-3-methoxy-benzamide
WO2010146478A1 (en) * 2009-05-08 2010-12-23 Ranbaxy Laboratories Limited Parenteral composition comprising a fluoroquinolone compound and a nitroimidazole compound
US8546566B2 (en) 2010-10-12 2013-10-01 Boehringer Ingelheim International Gmbh Process for manufacturing dihydropteridinones and intermediates thereof
US9358233B2 (en) 2010-11-29 2016-06-07 Boehringer Ingelheim International Gmbh Method for treating acute myeloid leukemia
US9370535B2 (en) 2011-05-17 2016-06-21 Boehringer Ingelheim International Gmbh Method for treatment of advanced solid tumors
JP2016525532A (ja) 2013-07-26 2016-08-25 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 骨髄異形成症候群の処置
KR101646324B1 (ko) * 2014-03-04 2016-08-05 동화약품주식회사 1-시클로프로필-6-플루오로-7-(8-메톡시이미노-2,6-디아자-스피로[3,4]옥트-6-일)-4-옥소-1,4-디히드로-[1,8]나프티리딘-3-카르복실산 디-아스파르트산염의 수화물 및 이를 포함하는 항균활성 조성물
US9867831B2 (en) 2014-10-01 2018-01-16 Boehringer Ingelheim International Gmbh Combination treatment of acute myeloid leukemia and myelodysplastic syndrome

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS497419A (da) * 1972-05-24 1974-01-23
JPS57188515A (en) * 1981-05-13 1982-11-19 Kyoto Yakuhin Kogyo Kk Stabilized aqueous dopamine preparation
ES512969A0 (es) * 1981-06-11 1983-02-16 Warner Lambert Co "un procedimiento para preparar sales de compuestos de naftiridina y quinoleina".
DE3306771A1 (de) * 1983-02-25 1984-08-30 Bayer Ag, 5090 Leverkusen Chinoloncarbonsaeuren, verfahren zu ihrer herstellung sowie diese enthaltende antibakterielle mittel
DE3333719A1 (de) * 1983-09-17 1985-04-04 Bayer Ag Loesungen milchsaurer salze von piperazinylchinolon- und piperazinyl-azachinoloncarbonsaeuren

Also Published As

Publication number Publication date
GR3002544T3 (en) 1993-01-25
US4957922A (en) 1990-09-18
EP0219784B1 (de) 1990-12-12
KR940002664B1 (ko) 1994-03-28
ZA868057B (en) 1987-06-24
CY1729A (en) 1994-05-06
FI864272A0 (fi) 1986-10-22
DE3676158D1 (de) 1991-01-24
PH26419A (en) 1992-07-15
NO864022D0 (no) 1986-10-09
EP0219784A3 (en) 1987-11-04
AU6432786A (en) 1987-04-30
PT83588B (pt) 1989-05-31
IL80380A (en) 1990-11-29
PT83588A (en) 1986-11-01
AU571796B2 (en) 1988-04-21
FI84555C (fi) 1991-12-27
SU1487801A3 (ru) 1989-06-15
DE3537761A1 (de) 1987-04-30
DK175494B1 (da) 2004-11-08
JPH0714879B2 (ja) 1995-02-22
FI84555B (fi) 1991-09-13
IL80380A0 (en) 1987-01-30
DK507886A (da) 1987-04-25
HK115593A (en) 1993-11-05
PL262006A1 (en) 1988-10-13
ATE59003T1 (de) 1990-12-15
EP0219784A2 (de) 1987-04-29
PL152336B1 (en) 1990-12-31
DD252125A5 (de) 1987-12-09
CA1282006C (en) 1991-03-26
ES2021571B3 (es) 1991-11-16
KR870003786A (ko) 1987-05-04
IE862803L (en) 1987-04-24
FI864272A (fi) 1987-04-25
NO864022L (no) 1987-04-27
HUT42952A (en) 1987-09-28
AR244085A1 (es) 1993-10-29
UA8033A1 (uk) 1995-12-26
NZ218016A (en) 1989-02-24
IE59385B1 (en) 1994-02-23
JPS6299326A (ja) 1987-05-08

Similar Documents

Publication Publication Date Title
DK507886D0 (da) Infusionsoplaesninger af 1-cyclopropyl-6-fluor-1,4-dihydro-4-oxo-7-(1-piperazinyl)-quinolin-3-carboxylsyre, lyofilisater og koncentrater og fremgangsmaade til deres fremstilling samt deres anvendelse
DE3574972D1 (de) 7-substituierte 1-cyclopropyl-6,8-difluoro-1,4-dihydro-4-oxo-3-chinolincarbonsaeure
DK514586D0 (da) Quinolinderivater, deres fremstilling og anvendelse
DK282986A (da) Substitueret quinolin og farmaceutisk praeparat indeholdende en saadan forbindelse
DK63482A (da) 1-ethyl-6-fluor-1,4-dihydro-4-oxo-7-(1-piperazinyl)-1,8-naph-thyridin-3-carboxylsyre-sesquihydrat,dets fremstilling og anvendelse
ES2038128T3 (es) Preparaciones farmaceuticas de ciprofloxacina.
ATE74910T1 (de) Wasserloesliches norfloxacinaddukt.
DK487686A (da) 2-substitueret quinolin og farmaceutisk praeparat indeholdende en saadan forbindelse
ES542898A0 (es) Procedimiento de obtencion de acido 1-etil-6-fluoro-1,4-di- hidro-4-oxo-7-(1-piperazinil)-3-quinolincarboxilico
MX9203502A (es) Derivados policiclicos de quinolina, naftiridina y pirazinopiridina.
DK224986D0 (da) Fremgangsmaade til varmebehandling af en stabil vandig lerdispersion
NO871576D0 (no) Anthranilsyrederivater og fremgangsmaate for deres fremstilling.
IL80514A (en) 1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-7-(4beta-hydroxyethyl piperazino)-quinoline-3-carboxylic acid,its preparation and antibacterial agents containing it
ES519330A0 (es) Procedimiento para la obtencion del clorhidrato del acido del 1-etil-6-fluoro-1,4-dihidro-4-oxo-7-(1-piperazinil)-3-quinolinico.
ATE65160T1 (de) Verwendung von chinolinderivaten zum schuetzen von kulturpflanzen.
IL85549A (en) 1-cyclopropyl-6,7-difluoro-1,4-dihydro-4 oxo-3-quinolinecarboxylic acid

Legal Events

Date Code Title Description
PUP Patent expired